证券代码：301408 证券简称：华人健康 公告编号：2025-054 安徽华人健康医药股份有限公司 关于召开2025年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 安徽华人健康医药股份有限公司（以下简称"公司"）于2025年7月18日召开 第五届董事会第十一次会议，审议通过了《关于提请召开2025年第三次临时股东会 的议案》，决定于2025年8月25日14:30以现场投票与网络投票相结合的方式召开公 司2025年第三次临时股东会，现将本次股东会的有关事项公告如下： 一、会议基本情况 1、会议届次：2025年第三次临时股东会 2、会议的召集人：公司董事会 3、会议召开的合法、合规性：本次会议的召开符合有关法律、行政法规、部 门规章、规范性文件和《公司章程》的规定。 4、会议召开的日期与时间： （1）现场会议召开日期与时间：2025年8月25日（星期一）下午14:30； （2）网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年8月25日 上午9:15-9:25，9:30-11:30，下午13:00-15: ...

一、董事会会议召开情况 证券代码：301408 证券简称：华人健康 公告编号：2025-052 安徽华人健康医药股份有限公司 第五届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 安徽华人健康医药股份有限公司（以下简称"公司"）第五届董事会第十一 次会议已于 2025 年 7 月 14 日以书面、邮件送达形式发出通知，并于 2025 年 7 月 18 日在公司 6 楼 601 会议室以现场结合通讯的方式举行，本次会议应到董事 9 名，实到董事 9 名，其中董事鲁勖、殷俊、赵春水、刘亮、程谋、李传润以通 讯表决方式出席。本次会议由公司董事长何家乐先生召集和主持，公司高级管理 人员列席了会议。本次会议的召集和召开符合相关法律法规及《公司章程》的规 定，做出的决议合法有效。 二、董事会会议审议情况 本次会议审议并通过如下议案： 1、审议通过《关于变更注册地址并修订<公司章程>的议案》 经董事会审议，同意公司根据《中华人民共和国公司法》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板 上市公司规范 ...

| 联系方式 | 变更前 | 变更后 | | --- | --- | --- | | 办公地址 | 合肥市包河工业区上海路 | 安徽省合肥市河北路 123 号 A1 | | | 18 号 | 栋 | | 邮政编码 | 230051 | | | 公司网址 | www.hrjkjt.com | | | 投资者联系电话 | 0551-62862668 | | | 传真 | 0551-63677610 | | | 电子邮箱 | zqb@hrjkjt.com | | 公司董事会秘书和证券事务代表联系地址、信息披露文件备置地点同时变更。 以上变更自 2025 年 8 月 18 日起正式启用，敬请广大投资者知悉。 证券代码：301408 证券简称：华人健康 公告编号：2025-051 安徽华人健康医药股份有限公司 关于变更办公地址的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 安徽华人健康医药股份有限公司（以下简称"公司"）将于近期搬迁至总部 办公大楼，公司办公地址将相应变更。除上述变更外，公司网址、电子邮箱等其 他联系方式均保持不变。本次变更后，公司办公地址及其他 ...

国浩律师（上海）事务所 关 于 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 二零二五年七月 国浩律师（上海）事务所 关于安徽华人健康医药股份有限公司 2025 年第二次临时股东大会之法律意见书 致：安徽华人健康医药股份有限公司 安徽华人健康医药股份有限公司 2025 年第二次临时股东大会 安徽华人健康医药股份有限公司（以下简称"公司"）2025 年第二次临时股 东大会于 2025 年 7 月 18 日召开。国浩律师（上海）事务所（以下简称"本所"） 经公司聘请，委派律师参加了公司本次股东大会的全过程，并根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）等法 ...

证券代码：301408 证券简称：华人健康 公告编号：2025-050 安徽华人健康医药股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 （1）现场会议召开时间：2025 年 7 月 18 日（星期五）下午 14：30。 （2）网络投票时间：通过深圳证券交易所互联网系统投票的时间为 2025 年 7 月 18 日 9:15-15:00；通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 7 月 18 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00。 2、现场会议召开地点：安徽省合肥市包河区上海路 18 号华人健康大厦 6 楼 601 会议室。 3、会议召开方式：本次会议采取现场投票和网络投票相结合的方式召开。 4、会议召集人：董事会。 5、会议主持人：董事长何家乐。 6、本次会议的召集、召开符合《中华人 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Huaren Health, indicating a steady growth in revenue and profit, alongside a relatively high PE ratio compared to industry averages [1][2] - As of July 8, Huaren Health's closing price was 14.42 yuan, with a PE ratio of 38.16 times and a total market capitalization of 5.768 billion yuan [1] - The company operates in the pharmaceutical retail and distribution sector, with a focus on traditional and Western medicines, health products, and medical devices [1] Group 2 - For the fiscal year 2024, Huaren Health reported a record revenue of 4.532 billion yuan, representing a year-on-year growth of 19.34%, and a net profit of 138 million yuan, up 20.09% from the previous year [1] - The first quarter of 2025 showed a revenue of 1.267 billion yuan, an increase of 14.71% year-on-year, and a net profit of 61.22 million yuan, reflecting a growth of 28.15% [2] - The company’s R&D expenses reached 29.39 million yuan, marking a 21.46% increase compared to the previous year, indicating a commitment to innovation and development [1]

Group 1 - The company held its fifth board meeting on June 26, 2025, with 9 directors present, and the meeting was convened by Chairman He Jiale [1] - The board approved the proposal to abolish the supervisory board, transferring its powers to the audit committee of the board [1] - The company will revise its articles of association accordingly and seek authorization from the shareholders' meeting for subsequent registration and filing [1] Group 2 - All proposals presented at the board meeting received unanimous approval with 9 votes in favor, and they will be submitted to the shareholders' meeting for review [2][3][4][5] - The company aims to enhance its governance structure and operational standards by revising relevant governance documents in accordance with applicable laws and regulations [2][5] - The second extraordinary shareholders' meeting is scheduled for July 18, 2025, combining on-site and online voting [6]

Core Viewpoint - The document outlines the procedures and responsibilities related to the resignation and departure of directors and senior management at Anhui Huaren Health Pharmaceutical Co., Ltd, ensuring compliance with relevant laws and maintaining corporate governance stability [1][3][4]. Group 1: Resignation Procedures - The company must complete the re-election of a director within 60 days if a resignation is submitted [1]. - Directors and senior management must provide a resignation report detailing the resignation date, reason, position, and any continued roles within the company [1]. - If a director's resignation results in the board falling below the legal minimum number of members, the original director must continue to perform their duties until a new director is appointed [3][4]. Group 2: Responsibilities and Obligations - Departing directors and senior management must hand over all relevant documents, seals, data assets, and unresolved matters within five working days after their resignation [5]. - They are required to cooperate with the company regarding any significant matters that occurred during their tenure and must not interfere with the company's operations post-departure [7]. - The loyalty obligations of departing directors and senior management remain in effect for three years after their resignation [7]. Group 3: Shareholding Restrictions - Departing directors and senior management are prohibited from transferring their shares within 12 months of the company's listing and are limited in the amount they can transfer during their tenure and for six months post-tenure [7].

General Principles - The company aims to strengthen management control over its subsidiaries and standardize internal operations to protect the rights of the company and its investors [1] - The company exercises shareholder rights through voting and appointing directors and supervisors to its subsidiaries, while also providing guidance and supervision [1][2] Management Principles - The management control over subsidiaries is intended to establish effective control mechanisms to enhance governance structure, asset management, and overall operational efficiency [1][2] - Subsidiaries must report significant business and financial matters that could impact the company [1][2] Establishment of Subsidiaries - The establishment of subsidiaries must comply with national laws and align with the company's strategic planning and core competitiveness [1][2] - Approval for establishing subsidiaries or mergers must follow the company's articles of association and investment management regulations [1][2] Governance Structure - The company collaborates with other shareholders to establish governance structures for subsidiaries, ensuring compliance with legal requirements [2] - The company appoints directors and supervisors to maintain governance oversight, with a majority of board members being company representatives [2][3] Financial Management - Subsidiaries must adhere to a unified accounting system and financial management practices dictated by the company [3] - Financial reports must be submitted timely, and the company has the right to audit and review subsidiary operations [3] Supervision and Accountability - The company supervises subsidiaries' operations, investments, and compliance with disclosure regulations [3] - Subsidiaries must maintain transparency and cannot engage in unauthorized financial activities [3] Miscellaneous Provisions - The provisions of this system will be executed in accordance with relevant laws and regulations, and the company board has the authority to interpret the system [4]

Core Viewpoint - The internal audit system of Anhui Huaren Health Pharmaceutical Co., Ltd. aims to ensure compliance, asset security, and the authenticity of financial reporting while enhancing operational efficiency and supporting the company's strategic development [2][4]. Group 1: Internal Control Objectives - Internal control is a process implemented by the board of directors, audit committee, management, and all employees to achieve control objectives [2]. - The goals of internal control include ensuring legal compliance in management, asset security, and the authenticity and completeness of financial reports [2]. Group 2: Internal Audit Structure - The company has established an internal audit department responsible for supervising business activities, risk management, internal controls, and financial information [4][6]. - The internal audit department reports to the board of directors and is supervised by the audit committee [4][6]. Group 3: Responsibilities of Internal Audit - The internal audit department is tasked with evaluating the effectiveness of internal controls, the authenticity of financial information, and the efficiency of business activities [4][5]. - Internal audit personnel must possess professional qualifications and adhere to ethical standards while conducting audits [4][10]. Group 4: Reporting and Evaluation - The internal audit department must report any significant deficiencies or risks in internal controls to the audit committee promptly [5][6]. - The audit committee is responsible for reviewing internal audit reports and providing written assessments of the effectiveness of internal controls to the board of directors [6][8]. Group 5: Compliance and Accountability - The company must disclose any significant deficiencies in internal controls to the Shenzhen Stock Exchange and outline the measures taken to address these issues [6][9]. - Internal audit personnel are protected by laws and regulations, and any obstruction or retaliation against them is prohibited [4][10].